Decoy Therapeutics Inc. (DCOY) Investor Relations Documents

Decoy Therapeutics Inc. (DCOY) investor relations documents from the company's IR site: 11 press releases. Read in-app with summaries. First-party data.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-03Press releaseDecoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platfor
2026-07-27Press releaseDecoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Con
2026-07-15Press releaseJuly 15, 2026 Decoy Therapeutics Stockholders Elect Patricia Gau... CAMBRIDGE, Mass., July 15, 2026 /PRNewswire/ -- Deco
2026-06-26Press releaseJune 26, 2026 Decoy Therapeutics, Inc. Announces Up to $21 Milli... HOUSTON, June 26, 2026 /PRNewswire/ -- Decoy Therape
2026-06-08Press releaseJune 8, 2026 Decoy Therapeutics' CEO to Participate in hVIVO Ca... Rick Pierce to join speakers from Boehringer Ingelhei
2026-06-03Press releaseDecoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors
2026-06-01Press releaseJune 1, 2026 Decoy Therapeutics Partners with hVIVO to Advance ... Collaboration supports Phase 1 and Phase 2a human pro
2026-05-26Press releaseDecoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board
2026-04-27Press releaseApril 27, 2026 Decoy Therapeutics to Present at Two Peptide Thera... CBO Peter Marschel to Lead HubXchange Roundtable on
2026-04-09Press releaseDecoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined
2026-04-02Press releaseApril 2, 2026 Decoy Therapeutics Regains Compliance with Nasdaq ... CAMBRIDGE, Mass. and HOUSTON, April 2, 2026 /PRNewsw

DCOY overview · DCOY earnings · DCOY financials · DCOY KPIs · DCOY ownership · DCOY peers · DCOY filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.